» Articles » PMID: 15778493

Resident Th1-like Effector Memory Cells in Pulmonary Recall Responses to Mycobacterium Tuberculosis

Overview
Date 2005 Mar 22
PMID 15778493
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

We recently described a model of Th1 recall responses based on segmental antigen challenge with purified protein derivative of Mycobacterium tuberculosis (PPD). Bronchoscopic instillation of 0.5 tuberculin units of PPD resulted in localized lymphocytic inflammation in PPD-positive subjects only. Recruited lymphocytes were predominantly CD4+ and were enriched for cells capable of PPD-specific interferon (IFN)-gamma production. In the current study, we investigated the mechanisms by which this localized recall response is mobilized. Bronchoscopic PPD challenge of skin test-positive subjects resulted in the production of CXCR3 ligands IFN-gamma-inducible protein (IP)-10 and monokine induced by IFN-gamma (Mig), but not of CCR5 ligands macrophage inflammatory protein-1alpha and regulated-upon activation, normal T-cell expressed and secreted, whereas skin test-negative subjects produced none of these chemokines. Baseline bronchoalveolar lavage (BAL) cells of skin test-positive subjects produced IP-10 and Mig in response to in vitro stimulation as well. Because IP-10 and Mig are IFN-gamma-inducible chemokines, these findings suggested that chemokine responses to PPD were facilitated by resident memory cells of the lung. Further studies confirmed that baseline BAL lymphocytes of PPD-positive subjects produce IFN-gamma in response to PPD, and that, compared with peripheral blood, BAL cells are preferentially enriched for PPD-specific lymphocytes. This IFN-gamma production is predominantly a function of CD4+ T cells that display the CD45RO+/CCR7- surface phenotype characteristic of effector memory cells.

Citing Articles

Human alveolar macrophages display marked hypo-responsiveness to IFN-γ in both proteomic and gene expression analysis.

Thiel B, Lundberg K, Schlatzer D, Jarvela J, Li Q, Shaw R PLoS One. 2024; 19(2):e0295312.

PMID: 38300916 PMC: 10833554. DOI: 10.1371/journal.pone.0295312.


Mucosal and systemic immune responses after a single intranasal dose of nanoparticle and spore-based subunit vaccines in mice with pre-existing lung mycobacterial immunity.

Vergara E, Tran A, Kim M, Mussa T, Paul M, Harrison T Front Immunol. 2023; 14:1306449.

PMID: 38130713 PMC: 10733481. DOI: 10.3389/fimmu.2023.1306449.


Distinct gene expression signatures comparing latent tuberculosis infection with different routes of Bacillus Calmette-Guérin vaccination.

Silver R, Xia M, Storer C, Jarvela J, Moyer M, Blazevic A Nat Commun. 2023; 14(1):8507.

PMID: 38129388 PMC: 10739751. DOI: 10.1038/s41467-023-44136-8.


Controlled human infection models in COVID-19 and tuberculosis: current progress and future challenges.

Morrison H, Jackson S, McShane H Front Immunol. 2023; 14:1211388.

PMID: 37304270 PMC: 10248465. DOI: 10.3389/fimmu.2023.1211388.


The potential value of Notch1 and DLL1 in the diagnosis and prognosis of patients with active TB.

Xie J, Chen Y, Chen S, Long H, Zhang W, Liu G Front Immunol. 2023; 14:1134123.

PMID: 37063841 PMC: 10090694. DOI: 10.3389/fimmu.2023.1134123.


References
1.
Stead W . Management of health care workers after inadvertent exposure to tuberculosis: a guide for the use of preventive therapy. Ann Intern Med. 1995; 122(12):906-12. DOI: 10.7326/0003-4819-122-12-199506150-00003. View

2.
Silver R, Wallis R, Ellner J . Mapping of T cell epitopes of the 30-kDa alpha antigen of Mycobacterium bovis strain bacillus Calmette-Guérin in purified protein derivative (PPD)-positive individuals. J Immunol. 1995; 154(9):4665-74. View

3.
Condos R, Rom W, Schluger N . Treatment of multidrug-resistant pulmonary tuberculosis with interferon-gamma via aerosol. Lancet. 1997; 349(9064):1513-5. DOI: 10.1016/S0140-6736(96)12273-X. View

4.
Qin S, Rottman J, Myers P, Kassam N, Weinblatt M, Loetscher M . The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain inflammatory reactions. J Clin Invest. 1998; 101(4):746-54. PMC: 508621. DOI: 10.1172/JCI1422. View

5.
Silver R, Li Q, Boom W, Ellner J . Lymphocyte-dependent inhibition of growth of virulent Mycobacterium tuberculosis H37Rv within human monocytes: requirement for CD4+ T cells in purified protein derivative-positive, but not in purified protein derivative-negative subjects. J Immunol. 1998; 160(5):2408-17. View